US2022349599A1PendingUtilityA1
LPS Priming of Stromal Cells to Generate LPS-Specific Exosome Educated Macrophages
Est. expiryFeb 12, 2038(~11.5 yrs left)· nominal 20-yr term from priority
C12N 5/0645F24F 11/50F24F 2110/10F24F 2110/40C12N 5/0663F25B 45/00F25B 2345/006C12N 2501/052C12N 5/0656F24F 11/38F24F 11/30F16L 41/008
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The disclosure relates to an ex vivo generated population of educated macrophages specific to LPS and methods of making and using such macrophages.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method for generating an educated macrophage, the method comprising the steps of:
isolating extracellular vesicles from a mesenchymal stem cell previously exposed to lipopolysaccharide (LPS), and co-culturing a CD14+ cell with the extracellular vesicles in vitro until the CD14+ cell acquires an anti-inflammatory macrophage phenotype.
2 . The method of claim 1 , wherein the CD14+ cell and the extracellular vesicles are co-cultured for at least 2 days.
3 . The method of claim 1 , wherein the mesenchymal stem cell was exposed to LPS for at least 2 hours.
4 . The method of claim 1 , wherein the mesenchymal stem cell is exposed to about 50 ng/ml to about 200 ng/ml LPS.
5 . A population of anti-inflammatory macrophages produced by the method of claim 4 , wherein the anti-inflammatory macrophage phenotype is characterized as CD206 high, PD-L1 high, PD-L2 high, CD16 high and CD73 high compared to control macrophages.
6 . The method of claim 1 , wherein the CD14+ cell is a macrophage.
7 . The method of claim 1 , wherein the CD14+ cell is a monocyte and wherein the CD14+ monocyte and the extracellular vesicle are co-cultured for at least 5 days.Join the waitlist — get patent alerts
Track US2022349599A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.